Company intelligence / Profile preview

Nianyan Pharmaceuticals

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Nianyan Pharmaceuticals is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of protein degradation therapies. The company leverages its proprietary platform to design molecular glues and proteolysis-targeting chimeras (PROTACs) aimed at previously undruggable targets in oncology and immunology. Its lead candidate, NY-001, is a GSPT1 degrader currently undergoing clinical evaluation for the treatment of advanced solid tumors. Nianyan is supported by prominent venture capital firms and focuses on expanding its pipeline of next-generation degraders to address significant unmet medical needs.

Therapeutic areas: OncologyImmunologyHematology
Modalities: Small moleculeProteolysis-targeting chimera therapyMolecular glue therapy
Industry: Biotech

Beyond the preview

Go deeper on Nianyan Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nianyan Pharmaceuticals.

Explore the full profile